Immune Thrombocytopenia and Cerebral Venous Sinus Thrombosis Following COVID-19 Vaccination: A Case Report

Abstract

Mass vaccination against coronavirus disease 2019 (COVID-19) has been safe and effective. The ongoing emergence of vaccine-induced complications has challenged the public trust in vaccination programs and, though uncommon, can lead to significant morbidity and mortality. Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a rare and fatal complication of the COVID-19 vaccine. We present a rare case of VITT in a young female who presented with worsening headache, body rash with deteriorating neurological deficit after 12 days of the second dose of the ChAdOx1 COVID-19 vaccine. Initial blood tests showed thrombocytopenia with deranged clotting time and D-dimer levels. Her computed tomography venogram showed thrombosis in the left transverse sinus, and she was diagnosed with a provisional diagnosis of VITT. She initially managed with dexamethasone, intravenous immunoglobulins, and apixaban to reverse the autoimmune process. Our case highlights the clinical course, diagnosis, and management of VITT, which will assist physicians in the timely recognition and adequate management of VITT.

COVID and Vaccine-related Cerebral Venous Thrombosis

“…Some cases have also been reported of CVT developing after the second dose of ChAdOx1 COVID-19 vaccine. 67–69…”

“…Excluding COVID vaccine-CVT case reports, most of the subjects experiencing CVT post-vaccination have been young females, 23–25, 58, 67, 70, 71 with the highest risk seen among females aged 30–49 years. 58 The time onset is usually within two weeks after the first dose.…”

“…Some cases have also been reported of CVT developing after the second dose of ChAdOx1 COVID-19 vaccine. [67][68][69] Excluding COVID vaccine-CVT case reports, most of the subjects experiencing CVT post-vaccination have been young females, [23][24][25]58,67,70,71 with the highest risk seen among females aged 30-49 years. 58 The time onset is usually within two weeks after the first dose.…”